

#### CLAIMS

1. A polypeptide comprising an amino acid sequence represented by SEQ ID NO: 9, or a polypeptide comprising an amino acid sequence having at least 70% homology with an amino acid sequence represented by SEQ ID NO: 9 and having an activity of inhibiting angiogenesis and/or an activity of inhibiting bone resorption.
2. The polypeptide according to claim 1, which further has amino acid residues added to the N-terminal and/or C-terminal thereof.
3. The polypeptide according to claim 2, wherein the amino acid residues added to the N-terminal thereof consist of an amino acid sequence beginning at methionine.
4. The polypeptide according to claim 2 or 3, wherein the amino acid residues added to the N-terminal and/or C-terminal thereof consist of an amino acid sequence containing a tag sequence consisting of 6 to 8 consecutive histidine residues and/or a FLAG tag sequence.
5. The polypeptide according to claim 2 or 3, wherein the amino acid residues added to the N-terminal and/or C-terminal thereof consist of an amino acid sequence of an *Aequorea victoria*-derived fluorescence protein or its analogue or a secretory alkali phosphatase or its analogue.
6. The polypeptide according to claim 1, wherein the amino acid residues added to the N-terminal and/or C-terminal thereof contain modified amino acid residues.
7. The polypeptide according to claim 6, wherein the amino acid residues added to the N-terminal thereof are glutamine or pyroglutamine residues.

8. The polypeptide according to claim 6, wherein the modified amino acid residues have at least one modified group selected from the group consisting of an acetyl group, formyl group, biotin group, Boc group and Fmoc group.
9. A nucleic acid molecule having a nucleotide sequence encoding an amino acid sequence represented by SEQ ID NO: 9.
10. A nucleic acid molecule having a nucleotide sequence from positions 4 to 243 in SEQ ID NO: 3, or a nucleic acid molecule which hybridizes under stringent conditions to a complementary sequence to the sequence from positions 4 to 243 of SEQ ID NO: 3 and having a nucleotide sequence encoding a polypeptide having an activity of inhibiting angiogenesis and/or an activity of inhibiting bone resorption.
11. A nucleic acid molecule having a nucleotide sequence encoding the polypeptide according to any one of claims 2 to 6.
12. A vector containing the nucleic acid molecule according to any one of claims 9 to 11.
13. A host cell transformed with the vector of claim 12.
14. A process for producing the polypeptide according to any one of claims 1 to 8, which comprises culturing the transformed host cell of claim 13 and recovering the expressed polypeptide.
15. The process for producing a polypeptide according to claim 14, which comprises recovering, in the presence of a protein denaturant, a polypeptide-containing extract from the transformed host cell.
16. The process for producing a peptide according to claim 14 or 15, which comprises treating the extract recovered from the

host cell with Triton X-114 followed by centrifuging it to remove a pyrogen.

17. The process for producing a polypeptide according to any one of claims 14 to 16, wherein the pH of the polypeptide-containing solution is adjusted in the range of pH 8.0 to 8.5 in all steps after recovery of the polypeptide-containing extract from the host cell.

18. A process for producing recombinant human ChM-I or recombinant human ChM1L by using a recombinant host cell capable of expressing human ChM-I or human ChM1L, which comprises recovering an extract containing human recombinant ChM-I or human recombinant ChM1L from the recombinant host cell in the presence of a protein denaturant, treating the extract with Triton X-114 and centrifuging it to remove a pyrogen.

19. The process according to claim 18, wherein the pH of the polypeptide-containing solution is adjusted in the range of pH 8.0 to 8.5 in all steps after recovery of the extract.

20. A pharmaceutical composition comprising the polypeptide according to any one of claims 1 to 8.

21. The pharmaceutical composition according to claim 20, which is an angiogenesis inhibitor and/or an inhibitor of osteoclast activation.

22. The pharmaceutical composition according to claim 21, which is a therapeutic agent for tendinitis, rheumatoid arthritis, arthritis deformans, malignant tumor, diabetic retinopathy, glaucoma, psoriasis, keloid, or arteriosclerosis.

23. A diagnostic composition for measuring a polypeptide having

an amino acid sequence represented by SEQ ID NO: 9 or 4 in components, which comprises at least an antibody or fragment thereof capable of recognizing the polypeptide of any of claims 1 to 7.

24. The diagnostic composition according to claim 23, which is used in diagnosis of any morbid state of tendinitis, rheumatoid arthritis, arthritis deformans and malignant tumor.

25. The diagnostic composition according to claim 23, which is used in diagnosis of any morbid state of diabetic retinopathy, glaucoma, psoriasis, keloid and arteriosclerosis.

26. A transgenic non-human animal manipulated genetically so as to contain the nucleic acid molecule according to any one of claims 9 to 11.